Major global pharmaceutical companies have published a new roadmap at a UK Government Department of Health event, aimed to combat anti-microbial resistance (AMR).
Titled ‘Roadmap for Progress on Combating Antimicrobial Resistance (AMR)’, the roadmap lays out commitments that the more than 13 pharmaceutical companies will deliver by 2020 to reduce AMR.
Out of the total pharmaceutical companies, ten are Association of the British Pharmaceutical Industry (ABPI) members.
The declaration emphasises a renewed cooperation in order to create sustainable markets for antibiotics and to renew basic scientific research and development to create a new generation of lifesaving drugs.
The roadmap has enlisted 15 specific actions that will be undertaken by the companies to address AMR by 2020.
The actions specifically include reduced environmental impact from the production of antibiotics; increased access to current and future antibiotics, vaccines, and diagnostics while ensuring antibiotics are used only by patients who need them.
ABPI research, medical, innovation executive director Dr Virginia Acha said: “By detailing specific actions companies will take in a proactive, ambitious and comprehensive roadmap, our industry is showing that it is committed to be held to account, and our action should be commended by all.
“On top of this, the UN’s General Assembly High-Level Declaration in New York, and on a local level by the UK Government last week, are also a welcome sign that this is not simply a problem for big pharma to resolve.
"Both rightly acknowledge that detecting, preventing and controlling resistance will require a strategic, coordinated, and sustained global and local response.
“Keeping antibiotics effective is everybody's responsibility, and in the UK, the ABPI and our members stand ready to work alongside policymakers, as well as the NHS, patients, healthcare providers, academia, the agricultural community and all global partners in this fight.”